Claude Opus 4.7 peer review identified critical manuscript weaknesses for JHO submission
Source type:
obs· Harvested: 2026-05-04 · Original date: 2026-05-04T06:19:18.266Z Metadata:{"project":"oncology-fih-research/oncology-fih-research","type":"discovery","obs_id":65447}
obs/65447 · discovery · 2026-05-04T06:19:18.266Z
Claude Opus 4.7 peer review identified critical manuscript weaknesses for JHO submission
The Claude Opus 4.7 simulated peer review completed analysis of manuscript/draft-v3-jho.md targeting Journal of Hematology & Oncology IF40 standards. The review scored the manuscript 41/100 and recommended reject-with-resubmission, identifying five fatal or near-fatal structural issues. The most critical finding is a category-level claim/evidence mismatch: the title and abstract position the work as a first-in-human landscape analysis, but only 10.4% of the 9659-trial cohort contains explicit FIH terminology. The broader “FIH-enriched” 50.6% includes any dose-finding/MTD/RP2D studies that may be follow-up expansions rather than true first-in-human trials, yet all descriptive tables report on the full 9659 cohort. Additional fatal concerns include single-author credibility gap for IF40 landscape papers (expected co-authorship from phase I units or pharmaco-epidemiologists), keyword-only methodology without manual validation against curated mechanism databases, weak hematology fit for JHO (one Discussion paragraph vs requirement for dedicated hem-onc tables and bispecific/CAR-T analysis), and circular site-consistency validation. The review provided eight prioritized revisions, with the highest-impact being restricting primary analysis to the strict FIH n=1004 subset, adding 200-trial manual validation with kappa statistics, and recruiting hem-onc co-author. Review acknowledged strengths including reproducibility scaffolding (R script, CSV, GitHub, API timestamp), nested cohort conceptual design, and defensible structural findings (China growth, industry transition). Bottom-line probability assessment estimated 55% desk rejection without external review at JHO/IF~40 tier, suggesting the manuscript may be better positioned at IF 8-15 oncology landscape journals after revisions.
Concepts: [“problem-solution”,“gotcha”,“why-it-exists”,“trade-off”]
Facts: [“Claude Opus 4.7 review returned score 41/100 for IF40 journal bar with reject-with-resubmission recommendation”,“Fatal concern #1: only 1004/9659 trials (10.4%) are explicit strict FIH, but title and abstract frame entire cohort as FIH landscape”,“Fatal concern #2: single-author urologic oncologist without phase I operational co-authors triggers desk-reject signal for IF40 hematology/oncology journal”,“Fatal concern #3: three-layer text-matching methodology (cohort identification, phase classification, modality tagging) lacks manual validation or external triangulation”,“Fatal concern #4: hematology content is one Discussion paragraph from text signals, no hem-onc stratified tables or bispecific/CAR-T trajectories for JHO fit”,“Fatal concern #5: site-network consistency analysis is circular validation using same registry source without external operational benchmarks”,“Top revision recommendation: restrict primary analysis to strict FIH subset n=1004, demote 9659 cohort to sensitivity supplement”,“Review estimated 55% probability desk rejection, 40% external review, 5-8% acceptance after revision at JHO/IF~40 level”,“Identified strengths: reproducibility scaffolding, nested cohort design, China growth signal (19→1341), industry transition (48%→80%), era stratification, figures quality”]
[← 回 Alfred Brain Hub]